BTOG 2023 | SYSTEMS-2: Radiotherapy and potential survival benefits in mesothelioma

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, describes what the primary data reveals from the SYSTEMS-2 clinical trial, a multi-center, randomized, Phase II study focused on patients with progressive mesothelioma. It aimed to observe whether better pain relief is associated with higher doses of radiotherapy compared to the standard dose. While the primary endpoint was not met, indicating no pain relief benefit, an unexpected survival benefit associated with the higher-dose arm was observed. At this stage, it is unsure whether this is due to the radiotherapy itself or confounding factors, necessitating further validation. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.